Stockscreener 앱 받기
96.81
1.40%
1.34
시간 외 거래:
96.95
0.14
+0.14%
전일 마감가:
$95.47
열려 있는:
$95.62
하루 거래량:
17.55M
Relative Volume:
1.46
시가총액:
$168.22B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
26.97
EPS:
3.5895
순현금흐름:
$7.40B
1주 성능:
-3.48%
1개월 성능:
-12.56%
6개월 성능:
-24.68%
1년 성능:
-26.09%
1일 변동 폭
$94.87
$97.14
1주일 범위
$93.92
$102.48
52주 변동 폭
$93.92
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
96.81 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
343.32 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.19 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.23 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.99 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
ABT: Abbott Laboratories Lowers Earnings Outlook Despite Revenue Beat - GuruFocus
How Abbott is Changing the Way We Treat AFib - Tomorrow's World Today
Abbott Laboratories (ABT) Margin Drop To 13.9% Challenges Bullish Earnings Narratives - simplywall.st
Ninety One UK Ltd Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Ninety One North America Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Abbott Laboratories stock (US0028241000): Why diagnostics strength is suddenly worth a closer look - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Short Interest Up 19.4% in March - MarketBeat
Abbott Reaches Preliminary Settlement in Derivative Governance Case - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
[8-K] ABBOTT LABORATORIES Reports Material Event - Stock Titan
ABT Maintained by Piper Sandler -- Price Target Lowered to $115 - GuruFocus
Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings - TipRanks
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi - GlobeNewswire Inc.
Abbott Laboratories Sales Growth Outlook 'Leaves Room For Upside': Analyst - Benzinga
Abbott stock crash: Rebound could be coming fast - MSN
Piper Sandler cuts Abbott Labs stock price target on weak diabetes sales - Investing.com
Abbott Stock Crash: Rebound Could Be Coming Fast - MarketBeat
TD Cowen lowers Abbott stock price target to $115 on guidance cut - Investing.com
ABT Maintained by Evercore ISI Group -- Price Target Lowered to $120 - GuruFocus
RBC Capital lowers Abbott Labs stock price target on Q1 results - Investing.com Australia
Abbott Labs’ Financial Results Narrowly Beat Forecasts - Baystreet.ca
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $115 to $144 - Moomoo
Abbott Laboratories (NYSE:ABT) Price Target Cut to $110.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Bernstein SocGen cuts Abbott Labs stock price target on growth concerns - Investing.com Canada
Citigroup Lowers Abbott Laboratories (NYSE:ABT) Price Target to $108.00 - MarketBeat
Oppenheimer Adjusts Price Target on Abbott Laboratories to $115 From $132, Maintains Outperform Rating - marketscreener.com
Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios - techi.com
Abbott lowers EPS guidance on Exact Sciences buy as shares slide - Fierce Biotech
Citigroup Cuts Price Target on Abbott Laboratories to $108 From $136, Maintains Buy Rating - marketscreener.com
Benchmark Adjusts Price Target on Abbott Laboratories to $120 From $145, Maintains Buy Rating - marketscreener.com
JPMorgan Adjusts Price Target on Abbott Laboratories to $110 From $123, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Abbott Laboratories to $109 From $122, Maintains Overweight Rating - marketscreener.com
Benchmark cuts Abbott Labs stock price target on valuation to $120 - Investing.com
Oppenheimer cuts Abbott stock price target to $115 on guidance - Investing.com
Abbott Laboratories (NYSE:ABT) Q1 2026 Earnings Call Transcript - Insider Monkey
Why Is Abbott Stock Trending Lower? - Trefis
Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.
Why Abbott Laboratories stock tumbled on Thursday - MSN
Abbott Laboratories Stock Tumbles 6% On Weak Q2 Earnings Guidance - TIKR.com
BofA cuts Abbott Labs stock price target on growth concerns - Investing.com
BofA cuts Abbott Labs stock price target on growth concerns By Investing.com - Investing.com Australia
Mizuho Adjusts Price Target on Abbott Laboratories to $115 From $125, Maintains Neutral Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $134, Maintains Outperform Rating - marketscreener.com
RBC Cuts Price Target on Abbott Laboratories to $130 From $135, Keeps Outperform Rating - marketscreener.com
Dr. Alexander Crider: There is a hidden cost to the Abbott verdict for premature babies - Chicago Tribune
Abbott price target lowered to $120 from $150 at BofA - TipRanks
Abbott Laboratories vs Medtronic: Which Stock Could Rally? - Trefis
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
자본화:
|
볼륨(24시간):